Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.39 |
| ▸ | ADH1B | P00325 | 2/20 | 0.39 |
| ▸ | ADH1C | P00326 | 2/20 | 0.39 |
| ▸ | ADH1A | P07327 | 2/20 | 0.39 |
| ▸ | ADH7 | P40394 | 2/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519857 | 1.00 | FAAH (0.42) | FAAHTSHRALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL7648107 | 0.98 | TSHR (0.46) | FAAHTSHRALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL28887822 | 0.98 | TSHR (0.46) | FAAHTSHRALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL3796966 | 0.98 | TSHR (0.46) | FAAHTSHRALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL25093190 | 0.98 | TSHR (0.46) | FAAHTSHRALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL1083082 | 0.82 | — | — | |
| SCHEMBL88378 | 0.79 | TSHR (0.62) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL6280918 | 0.78 | — | — | |
| SCHEMBL89641 | 0.78 | — | — | |
| SCHEMBL7535052 | 0.76 | TSHR (0.55) | FAAHTSHRALDH1A1ZDHHC20ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084932-B2 | Phenylethynylnaphthalene dyes and methods for their use | Sony Group Corporation (JP) | 2021-08-10 | — | — | US | claimed |
| CN-1950341-A | Naphthalimide derivatives for the treatment of cancer | UNIBIOSCREEN SA (BE) | 2007-04-18 | — | — | CN | claimed |
| US-6858608-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | claimed |
| WO-2005011573-A2 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | claimed |
| US-20030078263-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA SA (FR) | 2003-04-24 | — | — | US | claimed |
| JP-2002518063-A | — | — | 2002-06-25 | — | — | JP | claimed |
| EP-0778263-B1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | WELFIDE CORP (JP) | 2002-01-09 | — | — | EP | claimed |
| US-6235936-B1 | TRANSITION METAL CATALYST FOR ARYLATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-05-22 | — | — | US | claimed |
| EP-1088098-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND SOCIAL SERVICES (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999067254-A2 | MULTI-DRUG RESISTANT RETROVIRAL PROTEASE INHIBITORS AND USE THEREOF | THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | claimed |
| WO-1999067417-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | claimed |
| EP-0682519-A4 | ADENOSINE KINASE INHIBITORS. | GENSIA INC (US) | 1997-12-17 | — | — | EP | claimed |
| EP-0682519-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1995-11-22 | — | — | EP | claimed |
| WO-1994017803-A9 | ADENOSINE KINASE INHIBITORS | — | 1994-09-29 | — | — | WO | claimed |
| WO-1994017803-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | claimed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | claimed |
| EP-0094792-B1 | 7-OXABICYCLOHEPTANE SUBSTITUTED AMINO PROSTAGLANDIN ANALOGS | E.R. Squibb & Sons, Inc. (US) | 1988-11-17 | — | — | EP | claimed |
| EP-2673284-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| US-4663336-A | ANTICOAGULANTS | E. R. SQUIBB & SONS, INC. (US) | 1987-05-05 | — | — | US | disclosed |
| EP-0207684-A2 | 7-Oxabicycloheptane substituted diamide and its congener prostaglandin analogs | E.R. Squibb & Sons, Inc. (US) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078263-A1 | Chemical derivatives and their application as antitelomerase agents | TERT, TERF2, DUT | FAAH 4744/4885TSHR 3003/4885ALDH1A1 854/4885 |
| US-11084932-B2 | Phenylethynylnaphthalene dyes and methods for their use | CENPE, NR2E3, RCN1 | FAAH 3932/4885TSHR 115/4885ALDH1A1 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.